Combination Therapy Cuts Risk of Death in Hard-to-Treat Myeloma

J&J reports major survival gains with dual‑target myeloma regimen

Phase 3 data show strong benefit for two therapies

Combination therapy cuts risk of death in hard-to-treat myeloma

A combination treatment using two Johnson & Johnson immunotherapies outperformed standard care regimens in reducing the risk of disease progression and death among people with previously-treated myeloma. That’s according to new data from a late-stage clinical trial that tested Talvey (talquetamab) plus Tecvayli (teclistamab) as a combination therapy for people with hard-to-manage myeloma. The dual-med strategy was seen to specifically cut the ri…

Choosing Among BCMA-Directed Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Dr. Binod Dhakal, Dr. Carol Ann Huff, and Dr. Prerna Mewawalla discuss the growing number of BCMA-directed bispecific antibody options available for patients with relapsed/refractory multiple myeloma (RRMM) and the practical considerations that influence treatment selection.